Combination treatment of NU7441 with TMZ further improved the average survival by up to one month in tumor‐bearing animals, suggesting the therapeutic potential of combination therapy targeting DNA‐PKcs with TMZ to treat patients with Ep‐GBM. Here, PRKDC is linked to neoplasm.